PerkinElmer, Inc. 

(Public, NYSE:PKI)   Watch this stock   
Find more results for PKI
Oct 29, 2009
Q3 2009 Earnings Conference Call - Webcast
Oct 29, 2009
Q3 2009 Earnings Release
Sep 22, 2009
UBS Global Life Sciences Conference
Sep 10, 2009
Thomas Weisel Partners Healthcare Conference
More events from AOL Finance »    

Key stats and ratios

Q4 (Oct '09) 2008
Net profit margin 3.67% 6.51%
Operating margin 6.04% 9.06%
EBITD margin - 13.62%
Return on average assets 2.14% 4.29%
Return on average equity 4.05% 8.03%
Employees 8,500 -

Address

940 Winter Street
Waltham, MA 02451
United States - Map
+1-781-6636900 (Phone)
+1-781-4314255 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Options - Morningstar
Research Reports - Yahoo Finance
Annual Report (PDF) - AnnualReports.com

PerkinElmer, Inc. discussed on blogs

Ranking 700+ Mid-Cap Stocks by Profit Margin - NASD100.com - Daily ... - Investor's Resources - NASD100.com - Daily Stock Rankings - 14 hours ago
Ranking Healthcare Stocks by Upside Potential - NASD100.com ... - Investor's Resources - NASD100.com - Daily Stock Rankings - Nov 19, 2009

PerkinElmer, Inc. discussions

  View all discussions »

Description

Perkinelmer, Inc. is a provider of technology, services and solutions to the diagnostics, academic research, environmental monitoring and safety and security markets. During the fiscal year ended December 28, 2008 (fiscal 2008), the Company operated in two segments: Life and Analytical Sciences, and Optoelectronics. Subsequent to the fiscal 2008, the Company operates in two segments: Human Health and Environmental Health. In January 2009, it acquired Opto Technology Inc. (Opto Technology). In December 2008, the Company acquired Arnel, Inc. (Arnel). In December 2008, it shut down the Cellular Screening Fluorescence and Luminescence workstations business, Analytical Proteomics Instruments business, and Proteomics and Genomics Instruments business. In May 2009, the Company acquired Analytica of Branford, Inc. In September 2009, the Company acquired the genetic screening business of Surendra Genetic Labs, Pvt Ltd. and SYM-BIO Lifescience.

Officers and directors

Robert F. Friel
Chairman of the Board, President, Chief Executive Officer
Age: 53
Bio & Compensation - Reuters
Frank Anders Wilson CPA
Chief Financial Officer, Senior Vice President, Chief Accounting Officer
Age: 50
Bio & Compensation - Reuters
Richard F. Walsh
Senior Vice President - Human Resources, Chief Administrative Officer
Age: 56
Bio & Compensation - Reuters
Lapo Paladini Ph.D.
Senior Vice President, Chief Marketing Officer
Bio & Compensation - Reuters
Daniel R. Marshak Ph. D.
Senior Vice President, Chief Scientific Officer and President, Greater China
Age: 51
Bio & Compensation - Reuters
Joel S. Goldberg
Senior Vice President, General Counsel, Secretary
Age: 40
Bio & Compensation - Reuters
John A. Roush
Senior Vice President, President - Environmental Health
Age: 43
Bio & Compensation - Reuters
Michael L. Battles CPA
Vice President, Chief Financial Officer - Human Health
Age: 40
Bio & Compensation - Reuters
G. Robert Tod
Lead Director
Age: 69
Bio & Compensation - Reuters
Nicholas A. Lopardo
Director
Age: 62
Bio & Compensation - Reuters